Envestnet Asset Management Inc. Makes New Investment in Cellebrite DI Ltd. (NASDAQ:CLBT)

Envestnet Asset Management Inc. bought a new stake in Cellebrite DI Ltd. (NASDAQ:CLBT) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 26,372 shares of the company’s stock, valued at approximately $512,000.

Several other large investors also recently bought and sold shares of the company. Bosun Asset Management LLC grew its holdings in Cellebrite DI by 1.4% in the fourth quarter. Bosun Asset Management LLC now owns 43,307 shares of the company’s stock valued at $954,000 after purchasing an additional 584 shares during the last quarter. OneDigital Investment Advisors LLC grew its holdings in Cellebrite DI by 2.5% in the first quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company’s stock valued at $556,000 after purchasing an additional 688 shares during the last quarter. TD Waterhouse Canada Inc. grew its holdings in Cellebrite DI by 1.8% in the fourth quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company’s stock valued at $1,046,000 after purchasing an additional 859 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new stake in Cellebrite DI in the first quarter valued at $51,000. Finally, NewEdge Advisors LLC grew its holdings in Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company’s stock valued at $86,000 after purchasing an additional 3,352 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Up 0.1%

CLBT opened at $13.65 on Wednesday. The firm has a market cap of $3.27 billion, a P/E ratio of -14.22, a PEG ratio of 2.75 and a beta of 1.27. Cellebrite DI Ltd. has a 52 week low of $12.26 and a 52 week high of $26.30. The business’s fifty day simple moving average is $15.37 and its 200 day simple moving average is $18.29.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.01. The business had revenue of $107.55 million for the quarter, compared to analyst estimates of $109.36 million. Cellebrite DI had a positive return on equity of 35.36% and a negative net margin of 46.34%. The business’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.08 earnings per share. As a group, equities analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on CLBT. Needham & Company LLC reissued a “buy” rating and issued a $24.00 target price on shares of Cellebrite DI in a report on Friday, June 6th. JPMorgan Chase & Co. lowered their target price on Cellebrite DI from $29.00 to $25.00 and set an “overweight” rating on the stock in a report on Monday, May 12th. Finally, Wall Street Zen lowered Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.